Diabetologia:1型糖尿病和NOD小鼠胰腺淋巴结间质细胞的表型改变

2019-12-24 MedSci MedSci原创

当造血细胞(例如特定的树突状细胞亚群)和非造血细胞(例如淋巴结间质细胞[LNSC])向自身反应性T细胞呈递外周组织抗原时,两者均可介导淋巴结的耐受诱导。

当造血细胞(例如特定的树突状细胞亚群)和非造血细胞(例如淋巴结间质细胞[LNSC])向自身反应性T细胞呈递外周组织抗原时,两者均可介导淋巴结的耐受诱导。LNSCs通常调节T细胞的转运和存活,并通过发挥免疫抑制作用帮助维持外周耐受性。然而,自体免疫是否与LNSCs的致敏功能缺陷有关尚不清楚,对LNSCs在人体内的特征性研究也不多见。我们假设1糖尿病患者和NOD小鼠胰腺淋巴结T细胞反应异常可能与LNSC功能改变有关。

我们使用流式细胞术分析来自1糖尿病NOD小鼠的plnLNSC分布和表型。评估了来自人类供体的LNSCs的不同亚群中与耐受性相关的基因的表达,以及在自身免疫调节因子(AIRE)+细胞富集的树突状细胞群中(鉴定为HLA-DRhigh CD45low)的表达。

研究发现,在1糖尿病NOD小鼠中,不同LNSC亚群的相对频率均发生改变,而在人类1型糖尿病中,MHC II类和程序性死亡配体1 (PD-L1)表达均上调。耐受相关基因在小鼠和人类LNSCs的稳态表达谱相似,但在人类1型糖尿病中普遍上调,而与此同时,许多此类基因在富含air的树突状细胞群中下调。

研究显示,在1型糖尿病患者中,LNSCs发生了显著改变,但令人惊讶的是,它们显示出增强的致耐受性表型以及增加的抗原呈递潜能,这可能表明试图抵消树突状细胞相关的致耐受性缺陷。 因此,LNSC可以构成替代性治疗靶标,在其中传递抗原以帮助重新建立耐受性并预防或治疗1型糖尿病。

原始出处:

Jorge Postigo-FeRNAndezDonna L. FarberPhenotypic alterations in pancreatic lymph node stromal cells from human donors with type 1 diabetes and NOD mice

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639288, encodeId=cadf163928884, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Sep 05 16:20:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761258, encodeId=ad0c1e6125814, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 02 09:20:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293084, encodeId=94e01293084f5, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Dec 26 04:20:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535247, encodeId=ee0a153524e55, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Thu Dec 26 04:20:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042883, encodeId=570510428834f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Dec 24 16:20:00 CST 2019, time=2019-12-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639288, encodeId=cadf163928884, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Sep 05 16:20:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761258, encodeId=ad0c1e6125814, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 02 09:20:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293084, encodeId=94e01293084f5, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Dec 26 04:20:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535247, encodeId=ee0a153524e55, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Thu Dec 26 04:20:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042883, encodeId=570510428834f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Dec 24 16:20:00 CST 2019, time=2019-12-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639288, encodeId=cadf163928884, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Sep 05 16:20:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761258, encodeId=ad0c1e6125814, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 02 09:20:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293084, encodeId=94e01293084f5, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Dec 26 04:20:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535247, encodeId=ee0a153524e55, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Thu Dec 26 04:20:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042883, encodeId=570510428834f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Dec 24 16:20:00 CST 2019, time=2019-12-24, status=1, ipAttribution=)]
    2019-12-26 sodoo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1639288, encodeId=cadf163928884, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Sep 05 16:20:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761258, encodeId=ad0c1e6125814, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 02 09:20:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293084, encodeId=94e01293084f5, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Dec 26 04:20:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535247, encodeId=ee0a153524e55, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Thu Dec 26 04:20:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042883, encodeId=570510428834f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Dec 24 16:20:00 CST 2019, time=2019-12-24, status=1, ipAttribution=)]
    2019-12-26 tastas
  5. [GetPortalCommentsPageByObjectIdResponse(id=1639288, encodeId=cadf163928884, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Sep 05 16:20:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761258, encodeId=ad0c1e6125814, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Aug 02 09:20:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293084, encodeId=94e01293084f5, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Thu Dec 26 04:20:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535247, encodeId=ee0a153524e55, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Thu Dec 26 04:20:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042883, encodeId=570510428834f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Dec 24 16:20:00 CST 2019, time=2019-12-24, status=1, ipAttribution=)]
    2019-12-24 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Diabetes Care:1型糖尿病成年人大麻的使用与糖尿病酮症酸中毒风险增加有关

由此可见,1型糖尿病成年人使用大麻与DKA风险增加相关。提供者应告知其患者使用大麻可能引起DKA的潜在风险。

FDA批准用于1型糖尿病患者的新型闭环胰岛素输送系统

据外媒The Verge报道,美国食品药品管理局(FDA)周五批准了一种新型闭环胰岛素输送系统的使用,该系统可以使糖尿病患者自定义治疗方法并自动调整胰岛素水平。它将在2020年1月抵达患者手中。名为Control-IQ的技术由Tandem Diabetes Care制造,并与血糖传感器和胰岛素泵连接,以根据1型糖尿病患者的血糖水平自动增加,减少或停止胰岛素的输送。1型糖尿病患者无法产生自己的胰岛素

Diabetes Metab Syndr Obes:中国2万新确诊糖尿病分析,3.72%为自身免疫性糖尿病

一提1型糖尿病,常常会认为患者多为儿童,但近期中南大学湘雅二医院周智广团队进行的研究发现,成人中也并不少见,尤其是自身免疫性糖尿病(LADA)。

JCEM:1型糖尿病患者骨矿物质密度

由此可见,在各个年龄段中,T1D女性患者的腰椎BMD与没有糖尿病的年龄和性别相匹配的参与者相似,但绝经后的T1D女性患者腰椎、股骨颈和全髋BMD要低。

Diabetes Care:1型糖尿病年轻人自杀风险评估

由此可见,该研究的结果对具有自杀和死亡观念的1型糖尿病青壮年的行为和认知提供了初步了解。在常规的1型糖尿病门诊就诊期间,开展全面的自杀风险评估和安全计划是可行的。

JCEM:1型糖尿病女孩HbA1c升高与皮质和小梁微结构改变有关

由此可见,骨骼微结构在T1D疾病早期和较高的平均血糖个体有所改变。抑制的骨形成和较低的循环IGF-1可能会促进该改变。